The fungal type III polyketide synthase 2 0 -oxoalkylresorcylic acid synthase (ORAS) primes with a range of acyl-Coenzyme A thioesters (C 4 -C 20 ) and extends using malonyl-Coenzyme A to produce pyrones, resorcinols, and resorcylic acids. To gain insight into this unusual substrate specificity and product profile, we have determined the crystal structures of ORAS to 1.75 Å resolution, the Phe-252/Gly site-directed mutant to 2.1 Å resolution, and a binary complex of ORAS with eicosanoic acid to 2.0 Å resolution. The structures reveal a distinct rearrangement of structural elements near the active site that allows accommodation of long-chain fatty acid esters and a reorientation of the gating mechanism that controls cyclization and polyketide chain length. The roles of these structural elements are further elucidated by characterization of various structure-based sitedirected variants. These studies establish an unexpected plasticity to the PKS fold, unanticipated from structural studies of other members of this enzyme family.
INTRODUCTION
Polyketides, a diverse class of secondary metabolites with antibacterial and antitumor activity, are synthesized by polyketide synthases (PKSs), a family of enzymes and multienzyme complexes nearly as varied as the products they create (Austin and Noel, 2003; Watanabe et al., 2007) . In contrast to type I and type II PKSs, which are large multidomain enzymes or multisubunit complexes, respectively, type III polyketide synthases are self-contained homodimeric enzymes, where the single active site in each monomer iteratively catalyzes the priming, extension, and cyclization reactions needed to create a polyketide product (Jez et al., 2001) . In spite of their structural simplicity, type III PKSs produce a wide array of compounds, including pyrones, acridones, chalcones, stilbenes, and phloroglucinols (Schrö der, 1999) (Figure 1 ). The multiplicity of products hinges on the ability of type III PKSs to utilize a variety of acyl-CoA thioesters for priming, to extend with varying numbers of malonyl-CoA units, and also to cyclize the linear polyketide intermediate by any of several condensation reactions. Whereas type III PKSs from plants such as chalcone and stilbene synthase have been studied for many years, members of this family were recognized in bacteria more recently, and the first characterization of a fungal type III PKS was reported in 2007 (Funa et al., 2007) .
Filamentous fungi produce a variety of polyketide compounds, representatives of which are both highly toxic (aflatoxin) and pharmacologically useful (lovastatin). The known polyketide products of filamentous fungi have thus far been traced to the activity of type I PKSs (Cox, 2007) , but putative type III PKSs have also been uncovered by analyzing the recently sequenced genomes of organisms including Aspergillus oryzae, Magnaporthe grisea, and Neurospora crassa (Seshime et al., 2005) . The product of N. crassa open reading frame NCU04801.1 was recently confirmed to be a type III PKS which prefers long-chain acyl-CoAs for priming, carries out extension using malonylCoA, and produces pyrone, resorcinol, and resorcylic acid products (Funa et al., 2007) . Product profile analysis of this open reading frame identifies the pentaketide resorcylic acid 2 0 -oxoalkylresorcylic acid as the major product, and this enzyme was named 2 0 -oxoalkylresorcylic acid synthase (ORAS). ORAS is one of several known type III PKSs to use long-chain acyl-CoA substrates and produces tetraketide and pentaketide resorcylic acids using C 16 , C 18 , and C 20 CoA esters as starter units (Funa et al., 2007) . Alignment of ORAS and other type III PKSs of plant and bacterial origin reveals a carboxy-terminal extension of approximately 50 residues beyond similar enzymes (see Figure S1 available online), and ORAS is longer than the only other type III PKS known to have a carboxy-terminal extension, 1,3,6,8-tetrahydroxynaphthalene synthase (THNS) from Streptomyces coelicolor (Izumikawa et al., 2003) .
Structural analysis of Medicago sativa chalcone synthase (CHS) (Ferrer et al., 1999) , Pinus sylvestris stilbene synthase (STS) (Austin et al., 2004a) , Gerbera hybrida 2-pyrone synthase (2PS) (Jez et al., 2000) , and Aloe arborescens pentaketide chromone synthase (PCS) (Morita et al., 2007) from plants, and of the bacterial enzymes Mycobacterium tuberculosis Pks18 (Sankaranarayanan et al., 2004) and S. coelicolor THNS (Austin et al., 2004b) have provided useful insight into the basis of starter molecule specificity and mechanism of biosynthesis ( Figure 1 ). Although these enzymes share common core architectural features, subtle rearrangements of the polypeptide main chain and alteration of critical residues at the active site result in the functional diversity of the type III polyketide synthases. In order to elucidate the structural basis for long-chain starter molecule specificity and gain insights into the mechanism of pentaketide alkylresorcylic acid synthesis, we have determined the crystal structures of a fully active truncation variant of ORAS to 1.76 Å resolution, of the Phe-252/Gly site-directed mutant to 2.1 Å resolution, and of a binary complex of truncated ORAS with eicosanoic acid (a C 20 fatty acid) to 2.0 Å resolution. The crystal structures reveal a distinct rearrangement of structural elements near the enzyme active site that allows for accommodation of long-chain fatty acid esters and unique active site features that result in a reorientation of the gating mechanism for controlling cyclization pattern and polyketide chain length. These structures reveal an unexpected static nature of the acyl-binding tunnel and suggest mechanistic similarities to bacterial type III polyketide synthases (Sankaranarayanan et al., 2004) .
RESULTS

Expression of His-Tagged ORAS in Escherichia coli
The ORAS-encoding open reading frame NCU04801.1 was amplified from a library of N. crassa mRNA and initially cloned with an amino-terminal hexahistidine affinity tag. The purified recombinant protein was heterogeneous as judged by SDS-PAGE analysis due to degradation of the carboxy terminus. Consequently, the ORAS gene product was recloned with a carboxy-terminal hexahistidine tag preceded by a thrombin cleavage site. To determine whether the 50 residue carboxyterminal extension, observed upon alignment of ORAS with other type III PKS enzymes, is necessary for catalysis, a truncated mutant with a deletion of this extension (trORAS) was generated.
In Vitro Analysis of Recombinant ORAS
The steady-state kinetic parameters of trORAS and ORAS were determined for the priming substrate stearoyl-CoA from initial velocity measurements of the formation of free CoASH. Results for recombinant ORAS (K m = 3.9 mM and k cat = 6.7 3 10 À4 s À1 ) and trORAS (K m = 3.5 mM and k cat = 6.3 3 10 À4 s À1 ) are quite similar, indicating that the carboxy-terminal extension is not required for enzymatic activity. Our results reflect similar findings obtained for a 25 residue carboxy-terminal truncated variant of S. coelicolor THNS (see Figure S1 ), which was shown to possess activity similar to that of the wild-type enzyme (Austin et al., 2004b) . Additional comparison of the specific activity and product profile for trORAS and ORAS is provided in Figure S3 .
Structural Rearrangements in the Lower Domain of ORAS
Crystallization attempts of full-length ORAS were hampered by the propensity of the enzyme to degrade over the course of a few hours following purification. Mass spectrometric analysis of the degradation product suggested cleavage at residues located at the charged carboxy-terminal extension. Limited proteolysis confirmed that the residues at the carboxy terminus are labile and, as the variant lacking carboxy-terminal extension residues is shown to be fully catalytically competent, crystallization efforts were focused on this deletion variant. Screening of this truncated ORAS readily produced crystals utilizing polyethylene glycol 8000 as a precipitant. As attempts to solve the structure of trORAS by molecular replacement using the coordinates of other type III polyketide synthases were not successful, crystallographic phases were determined de novo using single-wavelength anomalous scattering from crystals grown from selenomethionine-incorporated protein. The resultant electron density map was of exceptional quality, permitting a trace of all residues from Ala-9 through Arg-388 in each monomer and refinement against a 1.75 Å resolution data set to a final R factor/ free R factor of 17.9%/20.8% (see Table 1 for further details).
The overall structure of trORAS recapitulates the characteristic bidomain fold observed in structures of other type III polyketide synthases (Jez et al., 2001) , albeit with novel distinguishing structural elements (Figure 2A) . A structure-based similarity search using the Dali search engine (Holm and Sander, 1995) queried against the Protein Data Bank (Berman et al., 2000) identifies chalcone synthase (Ferrer et al., 1999) as the closest structural homolog (Z score = 46.9, root-mean-square deviation [rmsd] of 2.2 Å over 355 residues aligned with a sequence identity of 24%). Two other homologs of note, which share a significant characteristic structural feature with ORAS (see below), are the bacterial type III PKS enzymes, particularly S. coelicolor THNS (Austin et al., 2004b ) (Z score = 42.8, rmsd of 2.3 Å over 344 residues aligned with a sequence identity of 24%), and M. tuberculosis Pks18 (Sankaranarayanan et al., 2004 ) (Z score = 44.2, rmsd of 2.2 Å over 346 residues aligned with a sequence identity of 24%) (see Figure 2B for a structurebased sequence alignment). b R sym = Sj(I i À < I i >)jSI i , where I i = intensity of the ith reflection and < I i > = mean intensity. c Mean figure of merit before and after density modification. d R factor = S(jF obs j À kjF calc j)/SjF obs j and R free is the R value for a test set of reflections consisting of a random 5% of the diffraction data not used in the refinement.
Although the core structure of trORAS is characteristic of that of other type III PKSs, the structure is set apart by significant deviations in the backbone relative to other enzymes of this family. The core ababa thiolase fold observed in the upper domains of type III PKS molecules is retained in the structure of trORAS, albeit with uncharacteristically long loop regions that vary in length in comparison with the closest structural homologs. Within one such loop region, the polypeptide backbone between a helix a12 and b sheet b12 adopts an a-helical configuration spanning residues Asp-355 through Leu-359.
The fold of the lower domain of trORAS, harboring the traditional ''floor'' of the type III PKS active site and containing residues that are thought to be critical for substrate and product specificities, is significantly different from that observed in other family members. Most notably, in comparisons with the structures of other type III PKSs, the loop that bridges helices a4 and a5 is shortened by about six amino acids, resulting in a depression at this juncture of the polypeptide fold. This shorter loop is compensated by an extension of residues Thr-188 through Gln-201 into the corresponding void. Unexpectedly, in this (C and D) Stick-figure representations of residues that are believed to be involved in catalysis and product/substrate specificity in the active sites of (C) ORAS and (D) CHS complexed with naringenin. The phenylalanine residues that function as steric gates to control specificity are colored in blue, and residues that are implicated in participating in mechanistic steering of intermediates are shown in orange.
region, residues Met-189 through Asp-198 form an a-helical insertion that bridges sheets b6 and helix a8 ( Figures  3A and 3B ). This novel structural element, which we term insertion a7i, has not to our knowledge been previously observed in any type III PKS enzyme. In order to compensate for this helical insertion, the helix that follows this insertion (a8) and typically spans nine residues (Leu-206 through Leu-214 in M. sativa CHS) (Ferrer et al., 1999) has been shortened to encompass only four residues in trORAS (Gly-206 through Leu-209) ( Figures 3A and 3B ). These novel structural elements result in a rearrangement of the lower domain at the floor of the active site, and the functional ramifications of this rearrangement are discussed below.
Active Site Architecture
As observed in crystal structures of related type III PKS enzymes, trORAS exists as an obligate homodimer and, upon dimerization, each monomer buries 2364 Å 2 of surface area. However, trORAS lacks the amino-terminal helical extension that crosses over between the two monomeric units as in the structures of M. sativa CHS (Ferrer et al., 1999) and A. arborescens PCS (Morita et al., 2007) . In addition, trORAS lacks the Met-137 residue of M. sativa CHS that is highly conserved in plant type III PKS and participates in intersubunit contacts by protruding into the neighboring monomer to complete the composite active site. Instead, an asparagine residue (Asn-125) is located at the equivalent position, resulting in a lack of crosssubunit interactions in the formation of the active site cavity. The opening at the active site that is required for the intersubunit protrusion of Met-137 in M. sativa CHS is occluded in trORAS by a reorganization of the backbone between His-148 and Cys-152. A similar situation is observed in the structure of M. tuberculosis Pks18 that contains Ala-148 at the equivalent position and a substitution of the glycine residue at the opening by a leucine that similarly occludes cross-subunit interactions (Sankaranarayanan et al., 2004) .
The catalytic triad, consisting of Cys-152, His-305, and Asn-338, is situated at a location and orientation similar to that observed in other related type III PKS enzymes ( Figures 3C and  3D ). Mutation of Cys-152 to threonine was performed on the truncated ORAS enzyme to confirm the identity of this residue as the catalytic cysteine. The substitution resulted in loss of activity, with no product observed after 1.5 hr incubation in the presence of substrate (see Figure S6 ). As observed in the structures of M. sativa CHS (Ferrer et al., 1999) and G. hybrida 2PS (Jez et al., 2000) , the electron density at Cys-152 is consistent with the oxidation of this residue into sulfuric acid. Despite considerable efforts, cocrystallization attempts with long-and medium-chain fatty acyl-CoA esters have not been successful. Of note is the fact that ORAS is devoid of any of the positively charged residues that have been observed to line the CoAbinding pockets of other bacterial and plant type III PKSs where they stabilize the charges on the phosphopantetheine. The lack of these stabilizing elements in ORAS may account for the inability to obtain a static binary complex in the time courses required for cocrystallization.
In addition to the active site cysteine (Cys-152) that presents the covalent attachment site necessary for polyketide chain extension (Austin and Noel, 2003; Jez et al., 2001) , ORAS also harbors a second cysteine residue (Cys-120) at a position equivalent to that of Cys-106 in S. coelicolor THNS (Abe et al., 2005b) . In this bacterial enzyme that catalyzes a malonyl-CoA-primed pentaketide formation, Cys-106 is presumed to regulate polyketide reactivity either by facilitating the enolization of the triketide carboxylate, by protonation of the triketide enolate, or by hemithioketal formation during the elongation stage. Site-directed mutagenesis of this cysteine results in derailment of polyketide elongation and in the formation of a triacetic acid lactone (Abe et al., 2005b) . The equivalent cysteine in trORAS (Cys-120) was mutated to serine to investigate the role of this residue. The Cys-120/Ser mutant diminished but did not abolish resorcinol production, and the decrease in activity due to this mutation was more pronounced for longer acyl-CoA substrates ( Figures S4-S6 ).
In the structure of trORAS, Cys-120 occupies a position analogous to Thr-132 in P. sylvestris stilbene synthase (STS) (Austin et al., 2004a) and M. sativa CHS (Ferrer et al., 1999) . Prior crystallographic and biochemical analysis demonstrates that the positioning of this residue is critical to the formation of a thioesterase-like hydrogen-bonding network that mediates aldol cyclization specificity (Austin et al., 2004a) . This CHS/STS ''aldol switch'' controls the partitioning of the tetraketide intermediate between two competing chemical paths. Analysis of the active site structure of trORAS reveals that the orientation of Cys-120 is similar to that of Thr-132 in CHS and precludes the formation of a thioesterase-like hydrogen-bonding network for partitioning of intermediates. Consequently, the mechanism for aldol condensation and aromatization by trORAS proceeds through a yet unidentified mechanism distinct from that of STS. In addition, alkylresorcinols are among the products identified for trORAS both in this and in prior studies (Funa et al., 2007; Goyal et al., 2008) , suggesting that the stable resorcylic acid is an intermediate that is further enzymatically decarboxylated by ORAS to yield the final alkylresorcinol product. The production of this carboxylated resorcylic acid intermediate by ORAS further distinguishes the mechanism of this enzyme from STS, which does not produce a stilbene carboxylate intermediate (Austin et al., 2004a) .
A Reorganized Steric Gate Controls Specificity
Prior biochemical and structural studies on plant and bacterial type III PKSs have established the importance of several residues near the active site in controlling substrate and product specificities, including Thr-197, Gly-256, and Ser-338 of M. sativa CHS. In the structure of ORAS, drastic rearrangements at the active site result in significantly deviant dispositions of residues Phe-252 (corresponding to Gly-256) and Met-189 (corresponding to (Figures 3C and 3D) . Specifically, the replacement of the smaller side chain of Thr-197 in M. sativa CHS with the larger Met-189 in ORAS is compensated by significant expansion of the polypeptide backbone in this region as a result of the a7i helical insertion. Consequently, this substitution actually results in an increase in the active site contour along the backbone at this region. This is in contrast with results obtained for pentaketide chromone synthase (PCS) and octaketide synthase (OKS) from A. arborescens, where the residue at the analogous position plays a crucial role in controlling product chain length. Replacement of Gly-207 in OKS with larger side chains results in a smaller active site cavity and alters specificity toward smaller pentaketide products (Abe et al., 2005a) , whereas replacement of Met-207 in PCS with smaller side chains (Abe et al., 2005b) increases the active site cavity of this enzyme and alters specificity to larger octaketide products. Surprisingly, mutation of the larger side chain of Met-189 in ORAS with threonine results in significant loss of activity without alterations to the product profile ( Figure S8 ). These data suggest a role for the side chains of Met-189 in orienting substrates in the active site, consistent with the observed binding mode for fatty acids in the trORAS-eicosanoic acid cocrystal structure (see later section for details).
The reorganization of the polypeptide backbone near Met-189 results in a compensatory movement of the flanking b sheet (b9 encompassing residues Leu-250 through Asp-255) into the resultant cavity. In addition, the glycine residue that occupies a critical position along this strand (Gly-256 in M. sativa CHS) is replaced with Phe-252 in ORAS, further constricting the walls of the active site along this face of the tunnel (Figures 3C and 3D) . As a consequence of these structural reorganizations, Phe-252 is now poised to serve as a steric gate to regulate product specificity, in a manner analogous to the role played by Gly-207 in OKS (Abe et al., 2005a) and Met-207 in PCS (Abe et al., 2005b) . Substitution of Phe-252 to glycine in the trORAS enzyme altered the product profile for long-chain acyl-CoA substrates (C 16 or larger) and specifically disrupted the production of pentaketide resorcinol and resorcylic acid products. With palmitoylCoA 5a (C 16 ) and monounsaturated oleoyl-CoA 6a (C 18 ) as substrates, minor pentaketide products 5h, 6g, and 6h observed for the wild-type enzyme were eliminated in the Phe-252/Gly mutant. The effect was most significant for stearoyl-CoA 7a (C 18 ) and arachidoyl-CoA 8a (C 20 )-primed reactions, which resulted in increased abundance of pyrone derailment products including hexaketide (7i, 8i) and heptaketide (7j, 8j) pyrones at the expense of the pentaketide resorcinol product (7h, 8h) (Figure 4 ). Taken together, these results suggest that the length and flexibility of very long (C 18 and C 20 ) saturated acyl-CoAs allow for extensive interactions along the hydrophobic tunnel Products confirmed by LC-MS/MS for trORAS are shown in red, those for the Phe-252/Gly mutant are shown in blue, and products observed for both enzymes are shown in green. Mass spectral analysis of these products is provided in Table S2. of the enzyme, where Phe-252 may play a role in stabilizing the extended linear polyketide chain such that enzymatic resorcinol production will be favored over lactonization in solution.
Structure of the Phe-252/Gly Mutant In order to confirm that the altered product profile of the Phe-252/Gly mutant is not a consequence of gross structural alterations, the crystal structure of this variant was determined to 2.1 Å resolution, using the coordinates of the unliganded enzyme as a search probe (final R factor/free R factor of 19.8%/25.5%). The overall structure of this variant is almost identical to that of the wild-type enzyme except that unbiased electron density maps clearly show the substitution of Phe-252 by Gly ( Figure 5A ). Interestingly, clear but discontinuous density can be observed near the active sites in two of the four molecules in the crystallographic asymmetric unit of this variant, and this has been modeled as a molecule of polyethylene glycol (presumably carried over from the crystallization media) ( Figure 5A ). The larger cavity created in the vicinity of the active site as a consequence of this mutation more easily accommodates the polyethylene glycol, and a similar ligand is also observed in the structure of S. coelicolor THNS (Austin et al., 2004b) .
The removal of the bulky aromatic side chain from the hydrophobic core of the active site does not compromise packing integrity, and there are minimal perturbations of either of the main-chain atoms as a consequence of the Phe-252/Gly mutation. The rmsd of main-chain atoms between wild-type and Phe-252/Gly trO-RAS is only 0.2 Å . Whereas the main-chain atoms of wild-type trORAS and the Phe-252/Gly mutant can be accurately superimposed, the side-chain atoms of a number of residues in the vicinity of Gly-252 are altered as a consequence of the mutation. Specifically, the side chains of active site residues Cys-152, Phe-210, Met-189, and a number of additional flanking residues are slightly displaced relative to their positions in the wild-type trORAS structure ( Figure 5B ). The lack of any gross structural perturbations as a consequence of the Phe-252/Gly mutation suggests that the derailment of polyketide extension in this variant is a direct consequence of alterations in the activity site cavity, consistent with the role of Phe-252 as a steric regulator of product specificity in ORAS.
A Static Acyl-Binding Tunnel Flanks the Elongation/ Extension Site
The active site cavity of ORAS is flanked by an acyl-binding tunnel similar to those observed in the structures of the bacterial type III PKSs M. tuberculosis Pks18 and S. coelicolor THNS (Austin et al., 2004b; Sankaranarayanan et al., 2004) . Although attempts to obtain cocrystals with various CoA esters failed, cocrystallization efforts of trORAS with long-chain fatty acids yielded diffraction-quality crystals, and the structure of a binary complex with eicosanoic acid (a C 20 fatty acid) has been determined to 2.0 Å resolution by molecular replacement, using the coordinates of the unliganded enzyme as a search probe (final R factor/free R factor of 17.3%/22.5%). Initial, unbiased electron density maps, calculated after a cycle of crystallographic refinement of the molecular replacement solution, revealed strong and continuous electron density corresponding to the entire C 20 fatty acid in two of the four molecules in the crystallographic asymmetric unit (corresponding to one ligand per biological dimer) ( Figures 6A and 6B) .
The eicosanoic acid C 20 fatty acid chain occupies a position similar to that observed for a myristic acid ligand in the structure of M. tuberculosis Pks18 (Sankaranarayanan et al., 2004 ) and a heptamer of polyethylene glycol in the structure of S. coelicolor THNS (Austin et al., 2004b) (Figures 6C-6E ). In the trORAS cocrystal structure, as in each of the bacterial type III PKSs, the ligand occupies a long acyl-binding tunnel that extends into the ''floor'' of the PKS active site. However, the carboxyl group of the eicosanoic acid ligand is significantly closer to the two active site cysteines of trORAS (Cys-152 Sg-O distance of 4.2 Å ; and Cys-120 Sg-O distance of 4.0 Å ) than observed for the distance between the ligands and the nucleophilic cysteine in either of the bacterial enzymes (Austin et al., 2004b; Sankaranarayanan et al., 2004) . Although the Sg carboxylate oxygen distances are far too large to suggest covalent linkages, the distance and stereochemical disposition between the carboxyl group of the fatty acid and the two cysteines are consistent with the mechanism of steering polyketide reactivity as suggested by biochemical studies of S. coelicolor THNS (Austin et al., 2004b; Sankaranarayanan et al., 2004) .
In the trORAS cocrystal structure, the location of the hydrophobic fatty acid tail of the eicosanoic acid ligand is distinct from that observed for ligand complexes of the bacterial type III PKSs (Austin et al., 2004b; Sankaranarayanan et al., 2004) . The hydrocarbon tail does not extend out into bulk solvent but rather is directed back inward into the protein and toward the dimer interface (Figures 6C-6E ). The trajectory of the hydrocarbon tail is restricted by the a7i helical insertion, which blocks the base of this lower domain of trORAS and guides the ligand back into the protein and away from bulk solvent. A key structural element that orients the hydrocarbon tail is the side chain of Met-189, which forms one side of the wall of the ligand-binding cavity. Mutational analysis demonstrates that replacement of Met-189 with a smaller threonine side chain significantly compromises catalytic activity with smaller-chain acyl-CoAs ( Figure S8 ), consistent with a role of this residue in guiding the binding of hydrocarbon tails of the fatty acid substrates.
During the review process for this manuscript, an independent report of the structure of unliganded ORAS was published by Sankaranarayanan and colleagues (Goyal et al., 2008) . Albeit A) Electron density map (shown in blue mesh and contoured at 2.5s) calculated using Fourier coefficients F obs À F calc with phases derived from the final refined model of Phe-252/Gly trORAS minus the atoms of residue Gly-252 and all active site ligands. Clear, but discontinuous, electron density can be observed near the vicinity of Gly-252 and has been modeled as a molecule of polyethylene glycol. The final refined coordinates of important active site residues are shown as stick figures, the polyethylene glycol is shown in pink. (B) A superposition of active site residues of wild-type trORAS (shown in pink) and the Phe-252/Gly variant (shown in blue). There are no significant changes in the main-chain atoms of the two structures and only small alterations in the position of the active site residues are shown.
of significantly lower resolution, the overall fold of the polypeptide is similar to that detailed in our 1.8 Å resolution structure of trORAS. However, these investigators fail to note the a7i helical insertion that distinguishes the reorganized active site of ORAS from other type III PKSs such as chalcone synthase (Ferrer et al., 1999) . In addition, poststructural biochemical analysis carried out by these investigators is based on a model of the fatty acid binding site derived from the structure of the bacterial M. tuberculosis Pks18 bound to myristic acid (Sankaranarayanan et al., 2004) . However, our 2.0 Å resolution cocrystal structure of trORAS bound to eicosanoic acid reveals that the trajectory of the hydrocarbon tail is distinct from that observed in the Pks18-myristic acid structure, and this novel fatty acidbinding tunnel is created by virtue of the a7i helical insertion (Figures 6C-6E) . Consequently, mutational analyses of ORAS based on the Pks18 cocrystal structure are likely not particularly Figure 6 . Close-Up View of the Active Site of trORAS Bound to Eicosanoic Acid (A and B) Orthogonal views of an electron density map (shown in blue mesh and contoured at 2s) calculated using Fourier coefficients F obs À F calc with phases derived from the final refined model of the ORAS-eicosanoic acid complex minus the atoms of the eicosanoic acid ligand. The final refined coordinates of important active site residues are shown as stick figures, the eicosanonic acid is shown in pink, and the a7 insertion is shown as a ribbon diagram in red. (C-E) Ribbon diagrams derived from the crystal structures of (C) trORAS (shown in blue) with bound eicosanoic acid, (D) Pks18 (shown in cyan) with bound myristic acid, and (E) THNS (shown in pink) with a bound molecule of polyethylene glycol. Each of the ligands is shown as CPK models and the respective active site cysteine residues are shown in ball-and-stick representation.
relevant. It is not surprising that mutations that were designed to sterically occlude the incorrectly identified substrate-binding tunnel (Ser-186/Phe) showed no changes in substrate preference (Goyal et al., 2008) . A second double variant (Ser-186/Phe/ Ser-340/Leu) was unable to synthesize any products from either short-or long-chain fatty acids (Goyal et al., 2008) , and this is likely a consequence of the fact that Ser-340 is immediately adjacent to the catalytic nucleophile (Cys-152) and mutations at this residue will likely interfere with substrate binding regardless of the chain length of the starter unit. The cocrystal structures presented in this current work and the corresponding mutational analyses unambiguously define a unique binding site for the long-chain hydrocarbon tail that distinguishes ORAS from other type III polyketide synthases.
The structures of the unliganded trORAS and the trORAS-eicosanoic acid complex are nearly identical and only small, subtle rearrangements of secondary structural elements along the atoms of the hydrocarbon tail are necessary to accommodate the ligand into the acyl-binding pocket. This is in sharp contrast with studies of S. coelicolor THNS and plant type III PKSs that suggest that the acyl-binding tunnel is dynamic and likely undergoes progressive, motional displacement during the extension of the aliphatic tail of polyketide intermediates (Austin et al., 2004b; Austin and Noel, 2003) . Particularly noteworthy is the fact that for each of the bacterial type III PKSs that harbors a bound ligand in the acyl-binding pocket, the ligand serendipitously either copurified with protein or was a product of the crystallization medium. No structures of these proteins are available in both the absence and presence of ligand (Austin et al., 2004b; Sankaranarayanan et al., 2004) . In contrast, our structure of wild-type unliganded trORAS is devoid of any extraneous ligands, and density for eicosanoic acid is present only when the ligand is explicitly introduced into the crystallization medium. These results have been reinforced by our observations of an unoccupied acyl-binding pocket in structures derived from over two dozen different data sets collected during the course of this work. The presence of a static acyl-binding tunnel may be a unique feature of this fungal type III PKS that distinguishes this enzyme from the bacterial enzymes. Alternatively, a welldefined tunnel may be characteristic of all type III PKS enzymes that utilize long-chain acyl-CoA esters as starter molecules. Further biochemical experiments are currently under way to distinguish between these possibilities.
SIGNIFICANCE
The 2 0 -oxoalkylresorcylic acid synthase (ORAS) of N. crassa is the only known type III polyketide synthase that can produce pentaketide resorcylic acids. The enzyme utilizes a long-chain fatty acid CoA ester starter molecule and carries out sequential condensations with four molecules of malonyl-CoA to yield the resorcylic acid. Our structural analysis of a truncated ORAS mutant reveals a unique rearrangement of secondary structural elements in the lower domain of the enzyme and a reorientation of the gating mechanism for controlling polyketide chain length and cyclization pattern. Similar to bacterial type III polyketide synthases, this fungal enzyme harbors a second active site thiol that may function in the mechanism of steering polyketide reactivity.
In the cocrystal structure of trORAS with the C 20 fatty acid eicosanoic acid, the hydrocarbon tail is accommodated within the protein interior within an extended acyl-binding pocket with a novel trajectory that results from the reorganized lower domain. The structure reveals an unexpected mechanism for sequestering large acyl groups that may be shared among other type III PKSs that utilize long-chain fatty acid CoA esters as starter molecules. These studies establish a framework for further engineering experiments aimed at exploiting the diversity of type III PKSs.
EXPERIMENTAL PROCEDURES Cloning
A complete listing of primers is given in Table S1 . Open reading frame NCU04801.1 (ORAS) was amplified from a library of N. crassa mRNA by reverse-transcription PCR in two steps using the First Strand cDNA synthesis kit (Roche Applied Sciences, Mannheim, Germany) and the specific primers FWD1 and REV1, followed by PCR amplification using the same primers. The resulting DNA product was restriction digested and inserted into pET15b to yield pET15b-ORAS. Subsequently, NCU04801.1 was reamplified using the above forward primer and a new reverse primer, REV2, and the resultant PCR product was digested and ligated into pET26b to yield pET26-trORAS. A thrombin protease site was engineered into the reverse primer in order to facilitate cleavage of the carboxy-terminal hexahistidine tag. A carboxy-terminal truncation variant of ORAS (trORAS) was amplified using the above forward primer and the reverse primer REV3, restriction digested, and ligated into pET15b to yield pET15b-trORAS. The DNA sequence of all constructs was verified. DNA sequencing was performed at the University of Illinois Biotechnology Center (Urbana, IL, USA).
Expression and Purification of Recombinant ORAS and trORAS
Plasmids pET26b-ORAS, pET15b-ORAS, and pET15b-trORAS were transformed into E. coli BL21 (DE3) and single colonies were used to inoculate 5 ml Luria broth containing 50 mg kanamycin/ml (pET26b) or 100 mg ampicillin/ml (pET15b). Following overnight growth at 37 C, this culture was used to inoculate 500 ml Terrific broth containing the appropriate antibiotic, and grown at 37 C until the optical density at 600 nm reached 0.8. Protein expression was induced with the addition of 0.25 mM isopropyl-b-D-thiogalactopyranoside (IPTG), and growth was continued for an additional 18 hr at 25 C. The flasks were chilled for 30 min, and then the cells were harvested by centrifugation (6000 3 g, 4 C, 15 min). The resulting pellet was resuspended in 2 ml lysis buffer (10 mM imidazole, 50 mM sodium phosphate buffer, 300 mM NaCl, 15% glycerol [pH 8.0], 1 mg/ml lysozyme) per gram cell weight and frozen at -80 C. Subsequently, cells were lysed using a French press and cellular debris was removed by centrifugation (40,000 3 g, 4 C, 10 min, twice). Recombinant proteins were purified by chromatography on Ni-NTA resin by virtue of the engineered carboxy-terminal (wild-type ORAS) or amino-terminal (trORAS) hexahistidine affinity tag. Captured protein was washed with wash buffers (20, 30, and 50 mM imidazole, 50 mM sodium phosphate buffer, 300 mM NaCl, 15% glycerol [pH 8.0]) and finally eluted in elution buffer (100 mM imidazole, 50 mM sodium phosphate buffer, 300 mM NaCl, 15% glycerol [pH 8.0]). The protein content of individual elution fractions was estimated using the Quick Start Bradford protein assay (Bio-Rad, Hercules, CA, USA) and the appropriate fractions were pooled and buffer exchanged into 10 mM MOPS buffer (pH 7.5) containing 15% glycerol overnight at 4 C. The protein was concentrated using an Amicon ultracentrifugal filter device (Millipore, Billerica, MA, USA). Representative SDS-PAGE analysis of recombinant protein is shown in Figure S2 . The hexahistidine tags were removed using the Thrombin Cleavage Capture kit (Novagen, Madison, WI).
Determination of Kinetic Parameters
Experiments to determine the kinetic parameters of wild-type and truncated ORAS enzyme with stearoyl-CoA were carried out in triplicate. Experiments were conducted according to the method of Funa et al. (2007) with some modifications. Each reaction contained 50 mM Tris-HCl (pH 7.0), 0.5 mM recombinant protein (ORAS or trORAS), and 100 mM malonyl-CoA in a total reaction volume of 400 ml. The concentration of priming acyl-CoA was varied between 0.5 and 10 mM stearoyl-CoA. Reaction mixtures were preincubated at 30 C for 4 min before addition of malonyl-CoA. After mixing, a 100 ml aliquot of the reaction was removed and stopped immediately by addition of 20 ml of a solution of 4% trifluoroacetic acid in water. Subsequently, a second aliquot was removed at 45 s and quenched by the same method. Samples were kept at 4 C until analysis by HPLC. The reactions were analyzed using an Agilent 1100 Series HPLC and ZORBAX SB-C 18 reverse-phase column (3.0 3 150 mm, 3.5 mm) (Agilent Technologies, Palo Alto, CA, USA) monitoring at 258 nm, with conditions as follows: 0.5 ml/min; 25 C; solvent A: 15 mM ammonium formate; solvent B: 90% methanol, 10% 10 mM ammonium acetate (pH 7.3), adjusted using acetic acid; 0-15 min, 5%-20% B, 15-20 min, 20%-100% B, 20-27 min, 100% B. Peaks at 7 min and 9.5 min corresponded to authentic malonyl-CoA and CoASH, respectively. The initial rates of CoASH production determined from these reactions were fitted to the MichaelisMenten equation using nonlinear least-squares regression analysis in Microcal Origin 5.0 (Microcal Software, Northampton, MA, USA) to calculate k cat and K M .
Preparation of ORAS Mutants and Product Profile Analysis
Site-directed mutants were created using the QuikChange Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA, USA). From the pET15b-trORAS plasmid, the primers 252-F and 252-R were used to generate the Phe-252/Gly mutant, 152-F and 152-R were used to generate the Cys-152/ Thr mutant, and 120-F and 120-R were used to generate the Cys-120/Ser mutant. The DNA sequence of each mutant was verified and the mutants were expressed by the same method as described for ORAS and trORAS.
Reactions for product profile analysis contained 50 mM Tris-HCl (pH 7.0), 4 mM recombinant protein (ORAS, trORAS, or mutant), and the concentration of priming acyl-CoA and malonyl-CoA was 200 mM in a total reaction volume of 250 ml. Reaction mixtures were incubated at 30 C for 1.5 hr followed by HPLC analysis as described in Supplemental Experimental Procedures. The polyketide products were characterized by liquid chromatography-quadrupole time-of-flight mass spectrometry on a Micromass Q-Tof Ultima (Waters, Milford, MA, USA). Mass spectrometry was performed at the University of Illinois Mass Spectrometry Laboratory (Urbana, IL, USA).
Crystallization
For crystallization efforts, truncated ORAS (trORAS) and the Phe-252/Gly mutant of truncated ORAS were purified as described above, and its aminoterminal polyhistidine tag was removed using thrombin (1 U/mg protein; GE Healthcare, Piscataway, NJ, USA). The protein was further purified by anionexchange (5 ml HiTrap Q; GE Healthcare) and size-exclusion chromatographies (Superdex 75 16/60; GE Healthcare). Selenomethionine-incorporated trORAS (SeMet trORAS) was produced by the method of van Duyne et al. (1993) and purified as described, except that 5 mM DTT was included in all of the buffers. Crystals of native and SeMet trORAS and the Phe-252/Gly mutant were grown by the hanging-drop vapor-diffusion method. In each case, 1.5 ml protein (5 mg/ml) was mixed with 1.5 ml precipitant solution containing 18% polyethylene glycol 8000, 100 mM HEPES (pH 7.5), with 1% polyethylene glycol 3350 as an additive. The mixture drop was equilibrated over a well containing the same precipitant solution at 20 C, and crystals reached their maximum size after 3 days. Crystals that diffracted to slightly higher resolutions could be produced by incubation at 4 C, but these crystals took several weeks to grow and were not easily reproduced. Hence, initial phase determination utilized crystals grown at 20 C and subsequent crystallographic refinement was conducted against data collected from a crystal grown at 4 C. Crystals were briefly immersed in a solution consisting of the crystallization liquor supplemented with 25% glycerol, prior to vitrification by immersion in liquid nitrogen. For crystallization of ligand complexes, the appropriate ligand was added to the protein to a final concentration of 2-5 mM prior to crystallization.
Phasing and Structure Determination
A four-fold redundant data set was collected from orthorhombic crystals of selenomethionine-substituted trORAS at the selenium absorption edge, to a limiting resolution of 2.0 Å (overall R merge = 8.6, I/s (I) = 2.4 in the highest resolution shell) utilizing a Mar 300 CCD detector (LS-CAT, Sector 21 ID-D, Advanced Photon Source, Argonne, IL, USA). The structure of trORAS was solved by single-wavelength anomalous diffraction utilizing anomalous scattering from the 14 selenium-substituted methionine residues per monomer. Data were indexed and scaled using the HKL2000 package (Otwinowski et al., 2003) . Selenium sites were identified using HySS (Grosse-Kunstleve and Adams, 2003) and the heavy-atom substructure was imported to SHARP (Bricogne, et al., 2003) for maximum-likelihood refinement and phase calculation, yielding an initial figure of merit of 0.425 to 2.2 Å resolution. Solvent flattening using DM (Cowtan and Main, 1998) further improved the quality of the initial map (solvent-flattened figure of merit = 0.696). The resultant electron density map was of exceptional quality and permitted most of the main-chain and 75% of side-chain residues to be automatically built using ARP/wARP (Perrakis et al., 1997) . The remainder of the model was fitted using XtalView (McRee, 1999) and further improved by rounds of refinement with REFMAC5 (Murshudov et al., 1997 (Murshudov et al., , 1999 and manual building. Subsequent rounds of model building and crystallographic refinement utilized data from a crystal of trORAS grown under similar conditions at 4 C that diffracted to 1.75 Å resolution (overall R merge = 7.7, I/s [I] = 4.8 in the highest resolution shell). Crossvalidation, using 5%-7% of the data for the calculation of the free R factor, was utilized throughout the model-building process in order to monitor building bias (Kleywegt and Brunger, 1996) . Crystals of Phe-252/Gly trORAS occupy a monoclinic setting. A three-fold redundant data set was collected to a resolution limit of 2.1 Å (overall R merge = 7.1, I/s [I] = 2.8 in the highest resolution shell) utilizing a Mar 225 CCD detector. The structure of Phe-252/Gly trORAS was determined to 2.1 Å resolution by molecular replacement using the refined coordinates of unliganded ORAS structure as a search probe. Multiple rounds of manual model building using XtalView (McRee, 1999) were interspersed with refinement using REFMAC5 (Murshudov et al., 1997 (Murshudov et al., , 1999 to complete structure refinement. Crossvalidation used 5% of the data in the calculation of the free R factor.
Crystals of the trORAS-eicosanoic acid complex also occupy a monoclinic setting. A four-fold redundant data set of the complex was collected to a Bragg limit of 2.0 Å (overall R merge = 8.1, I/s [I] = 3.9 in the highest resolution shell) utilizing a Mar 300 CCD detector. The structure of the trORAS-eicosanoic acid complex was determined to 2.0 Å resolution by molecular replacement using the refined coordinates of the unliganded trORAS structure as a search probe. Multiple rounds of manual model building using XtalView (McRee, 1999) were interspersed with refinement using REFMAC5 (Murshudov et al., 1997 (Murshudov et al., , 1999 to complete structure refinement. The eicosanoic acid ligand was manually built into the difference Fourier maps after the free R factor dropped below 30%. Crossvalidation used 5% of the data in the calculation of the free R factor.
For each of the structures, stereochemistry of the model was monitored throughout the course of refinement using PROCHECK (Laskowski et al., 1996) . Crystal parameters, data collection parameters, and refinement statistics for each of the structures are summarized in Table 1 .
ACCESSION NUMBERS
Coordinates have been deposited in the Protein Data Bank with accession codes 3EUO (Native ORAS), 3EUQ (ORAS F252G mutant), and 3EUT (ORASeicosanoic acid complex).
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Supplemental Data include eight figures, two tables, Supplemental Experimental Procedures, and Supplemental References and can be found with this article online at http://www.chembiol.com/cgi/content/full/15/10/ 1079/DC1/.
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